XML 96 R48.htm IDEA: XBRL DOCUMENT v3.25.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Astellas Gene Therapies, Inc. (Narrative) (Details)
$ in Thousands
 1 Months Ended 12 Months Ended 85 Months Ended
Dec. 31, 2024
USD ($)
target
indication
Aug. 31, 2024
Dec. 31, 2024
USD ($)
target
indication
Dec. 31, 2023
USD ($)
Dec. 31, 2024
USD ($)
target
indication
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Revenues     $ 57,800 $ 176,232  
Deferred revenues $ 7,556   7,556 0 $ 7,556
Deferred revenues, non-current 5,874   5,874 $ 0 5,874
Astellas Gene Therapies, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Royalty obligation, term   10 years      
Astellas Gene Therapies, Inc. | License          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contract with customer liability 20,000   20,000   20,000
Variable consideration amount $ 1,300,000   $ 1,300,000   $ 1,300,000
Maximum number of additional targets | target 4   4   4
Number of indications per target | indication 3   3   3
Agreement term         3 years
Number of targets | target 5   5   5
Astellas Gene Therapies, Inc. | Initial License          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contract with customer liability $ 6,500   $ 6,500   $ 6,500
Revenues 6,500        
Astellas Gene Therapies, Inc. | Additional License          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contract with customer liability 13,500   13,500   13,500
Deferred revenues 7,600   7,600   7,600
Deferred revenues, non-current $ 5,900   $ 5,900   $ 5,900
Revenue From Contracts With Customer, Underlying Options, Exercise Or Expiration Term 4 years